Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05369754 Not yet recruiting - Clinical trials for Coronavirus Disease 2019

A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, PK and Immunogenicity of YBSW015 in Healthy Subjects

Start date: July 2022
Phase: Early Phase 1
Study type: Interventional

This is phase Ia study to research YBSW015 injection which is a monomolecular bispecific antibody. The Primary objective is to evaluate the safety and tolerability of YBSW015 injection after a single intravenous injection at different doses in healthy subjects. The Secondary objective is to evaluate the pharmacokinetic characteristics and immunogenicity of different doses of YBSW015 injection after a single intravenous injection in healthy subjects. This study is a single-center, randomized, double-blind, placebo-controlled, single-dose escalation clinical trial.

NCT ID: NCT05369676 Completed - COVID-19 Patients Clinical Trials

To Evaluate SSD8432/ Ritonavir in Adults With COVID-19

Start date: May 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, double-blind, Phase 1b clinical trial to evaluate the safety, Pharmacodynamics, and Pharmacokinetic of SSD8432 combined with ritonavir tablets in adults with COVID-19.

NCT ID: NCT05369611 Enrolling by invitation - COVID-19 Clinical Trials

COVID-19 Experiences in the SELF Cohort

Start date: June 17, 2022
Phase:
Study type: Observational

Background: COVID-19 affected African Americans more than Whites. African Americans, especially women, have had higher rates of COVID-19 infections compared to Whites. They are also more likely to go to the hospital or die of this disease. Many researchers who looked into these issues lacked background data on the people they studied. SELF is a 10-year study of fibroids in African American women aged 23-35. Researchers already have a lot of data on these women. Asking how COVID-19 affected them can add context other studies lack. Objective: To describe the impact of the COVID-19 pandemic on young African American women and their families. Eligibility: Participants must be enrolled in SELF (Study of Environment, Lifestyle, and Fibroids). Design: Researchers will invite all women enrolled in SELF to participate in this natural history study. Participants will complete one questionnaire. They will answer the questions online. They may also choose to get a paper copy sent by mail. The survey will take no more than 15-20 minutes. All questions will relate to COVID-19. Participants will be asked if they had COVID-19. They will be asked if family, friends, or members of their community did. They will answer questions about their vaccine status and access to health care services. Participants will also answer questions about how the pandemic affected their lives. They will be asked about their job and if finding childcare was a challenge. They will be asked about money problems and how they coped. They will be asked about sleep problems and emotional distress. Participants will get a $30 gift card after they finish the survey.

NCT ID: NCT05367895 Active, not recruiting - COVID-19 Clinical Trials

Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose

Start date: July 30, 2022
Phase:
Study type: Observational

This is a retrospective test-negative case-control study of COVID-19 Vaccine (CoronaVac®) manufactured by Sinovac Research and Development Co., Ltd.The main purpose of this study is to measure vaccine effectiveness of homologous booster-dose vaccination with CoronaVac® against laboratory-confirmed symptomatic disease.

NCT ID: NCT05367843 Terminated - Clinical trials for SARS-CoV-2 Infection

A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins

Start date: June 20, 2022
Phase: Phase 1
Study type: Interventional

PRIME-2-CoV_Beta is the first clinical candidate based on the attenuated 2nd generation Orf virus (ORFV) vaccine platform which encodes for the structural spike (S)- and nucleocapsid (N) protein of SARS-CoV-2. The aim of the multivalent vaccine is to broaden the specific immune response against SARS-CoV-2 and to increase the probability of cross-protection against emerging variants.

NCT ID: NCT05366296 Withdrawn - COVID-19 Pandemic Clinical Trials

Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine

Start date: July 2022
Phase: Phase 1
Study type: Interventional

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen that causes a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19), which is spreading all over the world. This virus can cause acute respiratory distress syndrome (ARDS) with a high fatality rate. In this phase I first-in-human clinical trial, healthy volunteers in two dose cohorts will be vaccinated Lyophilized COVID-19 mRNA Vaccine (RH109) The aim of the study is to assess the safety, reactogenicity and Immunogenicity of the candidate vaccine and to characterize its immunogenicity.

NCT ID: NCT05366244 Recruiting - COVID-19 Clinical Trials

An Observational Study in Patients With Mild to Moderate COVID-19

Start date: May 2, 2022
Phase:
Study type: Observational

The purpose of this study was to observe real-world disease progression in mild-moderate COVID-19 patients with at least one risk factor for serve COVID-19 illness or death.

NCT ID: NCT05366231 Completed - COVID-19 Pneumonia Clinical Trials

Kesuting Syrup in the Treatment of Corona Virus Disease 2019 (COVID-19)

Start date: May 8, 2022
Phase: Phase 4
Study type: Interventional

This trial is an exploratory study, aiming to explore the preliminary efficacy and safety of Kesuting Syrup in the treatment of novel coronavirus pneumonia. It is planned to include a total of 200 cases. Kesuting Syrup test group: Lianhua Qingwen Granules control group = 1:1, each 100 cases in each group.

NCT ID: NCT05366205 Not yet recruiting - COVID-19 Clinical Trials

Immune Function in Elderly Patients With Mild to Moderate COVID-19 on Hemodialysis

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

This randomized controlled trial will focus on the effects of early oral nutritional supplementation on immune function in elderly patients with mild to moderate COVID-19 on maintenance hemodialysis. The purpose of this study is to determine whether early oral nutritional supplementation can improve immune function and clinical outcomes.

NCT ID: NCT05365750 Active, not recruiting - COVID-19 Testing Clinical Trials

COVID-19 Antibody and Reinfection Study

Start date: June 15, 2020
Phase:
Study type: Observational [Patient Registry]

The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO) members who have and have not had COVID-19 infection for serial antibody testing and PCR testing to: 1. Quantify antibody titers among participants over 9 months. 2. Determine the rates of asymptomatic, mild, and severe recurrent infection among participants with prior COVID-19. 3. Examine association between antibody titer levels and risk of recurrent infection using a case control analysis nested in the cohort.